Paul J. Fitzgerald
Neuroscience · Purdue University West Lafayette
Publications
117
Citations
5,164
Est. group size
—
Recurring co-author estimate
Active years
60
Publishing since 1967
Paul J. Fitzgerald studies brain chemistry related to mood and stress, particularly how neurotransmitters like norepinephrine, dopamine, and serotonin are produced and altered in the body, including through unconventional biochemical pathways (for example, whether alcohol or glucose can be converted into these signaling molecules). His work also explores potential treatments for depression, such as ketamine and cholinesterase inhibitors, often using mouse behavioral models like the forced swim test.
Publication output has fluctuated over the last decade, peaking in 2021, dropping sharply in 2022-2023, then rebounding with increased activity in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Loneliness, serotonin, and medial prefrontal cortex: some empirical and theoretical considerations
Pharmacology Biochemistry and Behavior · 2026
- Investigating whether alcohol is transformed to norepinephrine or dopamine in the mouse brain
Pharmacological Reports · 2025
- Endogenous conversion of alcohol to norepinephrine and epinephrine may contribute to hangover
Medical Hypotheses · 2025
- Several endocannabinoids and amino acids may be biosynthetically converted to catecholamines in vivo
Frontiers in Pharmacology · 2025
- Mouse Bio-behavioral Phenotyping Using a Digital Homecage Framework for Long-timescale, High-resolution, and Multi-factor Data Collection and Analytics
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- A novel relationship between norepinephrine and glutamate in aging: Implications for neurodegenerative disorders
Advanced Neurology · 2025
- DNA methylation changes in a pharmaco-epigenomic EWAS in depression: comparing fixed and response-guided dosing paradigms for ketamine in the KADS trial
Research Square · 2025
- Glucose may be biotransformed and then react with alcohol, fats, endocannabinoids, or various amino acids to form dopamine or norepinephrine in vivo
Frontiers in Pharmacology · 2025
- Long COVID may be treatable with noradrenergic transmission reducing drugs
Medical Hypotheses · 2025
- Frontal Alpha Asymmetry and Its Modulation by Monoaminergic Neurotransmitters in Depression
Clinical Psychopharmacology and Neuroscience · 2024
- Affective disorders and the loudness dependence of the auditory evoked potential: Serotonin and beyond
Neuroscience Letters · 2024
- Neural hyperexcitability in Angelman syndrome: Genetic factors and pharmacologic treatment approaches
Epilepsy Research · 2024
- Investigating whether alcohol is transformed to norepinephrine or dopamine in the mouse brain: preliminary findings
ChemRxiv · 2024
- Endogenous Opioids Contain Terminal Amino Acids That May Be Transformed to Catecholamines <i>In Vivo</i> and Modulate Pain
Journal of Exploratory Research in Pharmacology · 2024
- Is There a Novel Biosynthetic Pathway in Mice That Converts Alcohol to Dopamine, Norepinephrine and Epinephrine?
Molecules · 2022
- Medical Hypotheses×5
- Translational Psychiatry×2
- Nature Neuroscience×2
- PLoS ONE×2
- Behavioural Brain Research×2
- Cara L. Wellman
Neuroscience · Indiana University
- Laurence Coutellier
Neuroscience · The Ohio State University
- Andrew R. Burke
Neuroscience · Indiana University
- Amanda Ringland
Neuroscience · The Ohio State University
- Marian L. Logrip
Neuroscience · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile